Repligen Corporation (RGEN): Price and Financial Metrics

Repligen Corporation (RGEN)

Today's Latest Price: $84.90 USD

0.06 (-0.07%)

Updated Feb 26 2:44pm

Add RGEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

RGEN Stock Summary

  • RGEN's current price/earnings ratio is 221.16, which is higher than 97.31% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for RGEN is currently 94.11, higher than 96.41% of US stocks with positive operating cash flow.
  • RGEN's price/sales ratio is 20.52; that's higher than the P/S ratio of 94% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Repligen Corp are SPSC, PAYC, CCMP, NCR, and LMAT.
  • Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to
RGEN Daily Price Range
RGEN 52-Week Price Range

RGEN Stock Price Chart More Charts

RGEN Price/Volume Stats

Current price $84.90 52-week high $109.94
Prev. close $84.96 52-week low $52.87
Day low $84.66 Volume 317,888
Day high $87.41 Avg. volume 368,268
50-day MA $97.63 Dividend yield N/A
200-day MA $86.42 Market Cap 4.42B

Repligen Corporation (RGEN) Company Bio

Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.

RGEN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$84.90$6.89 -93%

We started the process of determining a valid price forecast for Repligen Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Repligen Corp ranked in the 10st percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Repligen Corp ended up being:

  • 95% of the company's capital comes from equity, which is greater than 84.03% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 15.93% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • As a business, Repligen Corp experienced a tax rate of about 12% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 54.85% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Repligen Corp? See MEDS, PRSC, LCTC, SRDX, and BSX.

RGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

RGEN Latest Social Stream

Loading social stream, please wait...

View Full RGEN Social Stream

RGEN Price Returns

1-mo -14.78%
3-mo -5.55%
6-mo -8.52%
1-year 42.47%
3-year 164.24%
5-year 230.22%
YTD -8.22%
2019 75.39%
2018 45.37%
2017 17.72%
2016 8.94%
2015 42.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8269 seconds.